Federated Investors Inc. PA reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 591,406 shares of the medical device company’s stock after selling 24,922 shares during the period. Federated Investors Inc. PA owned approximately 0.65% of DexCom worth $70,437,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Laurel Wealth Advisors LLC bought a new stake in shares of DexCom during the fourth quarter valued at approximately $26,000. Private Ocean LLC bought a new stake in shares of DexCom during the first quarter valued at approximately $36,000. Canton Hathaway LLC bought a new stake in shares of DexCom during the first quarter valued at approximately $41,000. Bremer Bank National Association bought a new stake in shares of DexCom during the first quarter valued at approximately $42,000. Finally, Bremer Trust National Association bought a new stake in shares of DexCom during the fourth quarter valued at approximately $49,000. 96.41% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:DXCM traded down $1.99 during mid-day trading on Wednesday, hitting $141.53. The company had a trading volume of 833,828 shares, compared to its average volume of 1,318,214. DexCom, Inc. has a fifty-two week low of $90.61 and a fifty-two week high of $157.50. The company has a fifty day moving average price of $129.36. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57. The stock has a market capitalization of $13.00 billion, a price-to-earnings ratio of 471.77 and a beta of 0.70.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.12. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The company had revenue of $280.50 million during the quarter, compared to the consensus estimate of $246.10 million. During the same period in the prior year, the company earned ($0.30) earnings per share. The company’s revenue for the quarter was up 52.1% compared to the same quarter last year. As a group, research analysts anticipate that DexCom, Inc. will post 0.81 earnings per share for the current year.
A number of analysts have recently issued reports on DXCM shares. UBS Group lowered their price objective on DexCom from $150.00 to $140.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 30th. Northland Securities reiterated a “hold” rating and issued a $125.00 price target on shares of DexCom in a research report on Thursday, June 6th. BMO Capital Markets upped their price target on DexCom from $167.00 to $172.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Raymond James lowered their price target on DexCom from $160.00 to $150.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Finally, ValuEngine cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 1st. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. DexCom presently has a consensus rating of “Buy” and an average price target of $150.65.
In other DexCom news, EVP Steven Robert Pacelli sold 3,596 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $116.61, for a total value of $419,329.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $115.05, for a total value of $46,020.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,045 shares of company stock valued at $8,237,976. 0.88% of the stock is owned by corporate insiders.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How interest rates affect municipal bond prices
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.